Fast Track Group FTRK 深 沪
等待开盘 02-02 09:30:00 美东时间
0.755
-0.033
-4.20%
华盛通- 最 高0.755
- 今 开0.75
- 成交量 2.67万股
- 最 低 0.7021
- 昨 收 0.7881
- 总市值 1646.84万
- 52周最高 9.69
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 0.2916
- 委 比 -86.11%
- 总股本 2181.25万
- 历史最高 9.69
- 量 比 0.34
- 振 幅 6.71%
- 历史最低 0.2916
- 每 手 1
- 风险率 1.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics provided an update on its activities for Q2 FY26, highlighting advancements in its MSA program, Phase 2 data strengthening, and planning for a pivotal Phase 3 trial. The company presented additional analyses of the Phase 2 trial at international congresses, including improved efficacy signals for ATH434 at the 75 mg dose. Regulatory planning for an End-of-Phase 2 meeting with the FDA in mid-2026 is progressing, with a focus ...
01-30 12:25
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Radiopharm Theranostics reported interim results from its Phase 2b clinical trial of RAD 101, with 92% of evaluable participants achieving MRI concordance. Additional interim data from Phase 1 trials of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026. The company ended December 2025 with a cash balance of approximately $34.52 million, providing runway into 2027 to advance its pipeline. RAD 202 and RAD 204 showed promising sa...
01-28 12:00
FAST TRACK GROUP's Fast Track Entertainment Signs MOU With Leanbranding To Support Global Growth Of Rising K-Pop Girl Group KIIRAS
FAST TRACK GROUP (NASDAQ:FTRK) ("Fast Track" or the "Company"), a leading entertainment-focused event management and celebrity agency company, announced that Fast Track Entertainment ("FTE") has signed a Memorandum
01-27 22:08
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
BriaCell Therapeutics Corp. announced positive Phase 2 survival data for patients with metastatic breast cancer treated with the Bria-IMT regimen. Nine of 25 patients treated since 2022 remain alive 18-47 months post-enrollment, exceeding benchmarks for standard therapies. No Bria-IMT-related discontinuations were reported, and the regimen continues under US FDA Fast Track Designation. These findings support the potential of Bria-IMT to significa...
01-27 12:30
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
Greenwich LifeSciences reported increased cash reserves through its ATM financing, reaching $12.5 million, which may cover 2026 expenses. CEO Snehal Patel highlighted cost-saving strategies and the success of FLAMINGO-01, a Phase III trial showing an 80% reduction in breast cancer recurrence rates, aligning with Phase IIb results. The trial's open-label data indicates favorable immune responses and safety profiles across HLA types.
01-27 11:00
Adagene Provides Business Update and 2026 Objectives
Adagene Inc. reported unaudited cash of $74.5M as of Dec 31, 2025, providing runway into late 2027. Key 2025 achievements include Phase 1b/2 trial results for muzastotug in MSS CRC, FDA Fast Track designation for muzastotug + pembrolizumab, regulatory alignment with FDA, and initiation of a randomized Phase 2 trial. Strategic partnerships with Sanofi, Third Arc Bio, Exelixis, and ConjugateBio advanced masked antibody therapies. 2026 objectives in...
01-23 13:00
FAST TRACK GROUP Rebrands To Fast Track Entertainmen
FAST TRACK GROUP (NASDAQ:FTRK) ("Fast Track" or the "Company"), a leading entertainment-focused event management and celebrity agency company, announced its rebrand to Fast Track Entertainment, marking an evolution
01-20 22:06
Fast Track Events Rebrands to Fast Track Entertainment, Marking a Strategic Evolution Beyond Events
Fast Track Group rebrands as Fast Track Entertainment, expanding beyond event management to a broader entertainment platform focused on long-term influence and collaborations. Centered in Asia, the company aims to shape global entertainment, leveraging celebrity partnerships and cultural engagement. CEO Harris Lim emphasizes that entertainment builds lasting impact, beyond fleeting event moments. As Fast Track Entertainment evolves, it strengthen...
01-20 14:00
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
Mesoblast Limited has received positive feedback from the FDA regarding its allogeneic cell therapy rexlemestrocel-L for treating chronic discogenic low back pain (CLBP). The FDA acknowledged the pain reduction benefits and potential inclusion of opioid reduction data in the product labeling. Mesoblast is currently conducting a second Phase 3 trial, with over 50% enrollment, targeting 300 patients. The company highlights the product's potential t...
01-19 00:01
Fast Track Group reports 1H results
Fast Track Group press release (FTRK): 1H Revenue of $937K. Gross Profit significantly increased to $376,024 (gross margin of 40%) for the six months ended August 31, 2025 compared to $598 (gross marg...
01-14 05:08
